Histogen 2013 MESA Presentation

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • Arashi
    replied
    Originally posted by Thinning87
    Use your brain:

    The reason the numbers are different is because the 60% growth referred to a single case. The 10 and 19% figures are averages...
    Yup. Next to that photo stating +61%, you'll see the number of the patient (s1016) who got those results.
    Obviously it's a patient with very thin recpient, so if you only have a few hairs, the higher the increase in percentage will be of course. Hence I think an absolute number would be way more interesting to see than a percentage

    Leave a comment:


  • Thinning87
    replied
    Originally posted by Scientalk56
    http://www.histogen.com/downloads/sc...2013-final.pdf

    What i noticed that:
    1- Histogen Phase I/II Clinical Trial did not show photos, just detailed statistics (Male Patients)
    2- Dr. Craig Ziering US Physician-sponsored Trial – showed photos, with no detailed statistics (Female patients)


    what i don't get:

    Phase I/II Clinical Trial – 56 Subjects
    PRIMARY SAFETY 12 weeks
    • Clinical chemistry showed no indication of toxicity or blood/urine abnormalities
    PRIMARY EFFICACY 12 weeks
    10.45% increase in mean total hair count over baseline p=0.0013
    19.5% increase in mean terminal hair count over baseline p=0.0135
    • 86% responder rate

    WTF with 10.45% and 19.4% increase? isn't that supposed to be 60% ?
    and no, don't answer that. the only one who can explain that is Dr gail. because you will give me answers based on 7th grade math class.


    Enjoy..
    Use your brain:

    The reason the numbers are different is because the 60% growth referred to a single case. The 10 and 19% figures are averages...

    Leave a comment:


  • Scientalk56
    started a topic Histogen 2013 MESA Presentation

    Histogen 2013 MESA Presentation



    What i noticed that:
    1- Histogen Phase I/II Clinical Trial did not show photos, just detailed statistics (Male Patients)
    2- Dr. Craig Ziering US Physician-sponsored Trial – showed photos, with no detailed statistics (Female patients)


    what i don't get:

    Phase I/II Clinical Trial – 56 Subjects
    PRIMARY SAFETY 12 weeks
    • Clinical chemistry showed no indication of toxicity or blood/urine abnormalities
    PRIMARY EFFICACY 12 weeks
    10.45% increase in mean total hair count over baseline p=0.0013
    19.5% increase in mean terminal hair count over baseline p=0.0135
    • 86% responder rate

    WTF with 10.45% and 19.4% increase? isn't that supposed to be 60% ?
    and no, don't answer that. the only one who can explain that is Dr gail. because you will give me answers based on 7th grade math class.

    Enjoy..
Working...